

研究成果の刊行に関する一覧表

書籍

著者氏名	論文タイトル名	書籍全体の編集者名	書 籍 名	出版社名	出版地	出版年	ページ
和田 隆志	急速進行性腎炎症候群 (ANCA関連腎炎を含む)	福井次矢・高木誠・小室一成	今日の治療指針 2020	医学書院	東京	2020	602-604
古澤嘉彦	神経疾患における患者レジストリの意義と可能性	水澤英洋 / 古澤嘉彦	脳神経内科	科学評論社	東京	2020	265-270
福井亮	難病データベースの現状と展望	内田章義	腎臓内科	科学評論社	東京都	2021年1月	120-128
井田博幸	小児慢性特定疾患児童成人移行期支援モデル事業		医学のあゆみ	医歯薬出版(株)		平成30年	901-906
井田博幸	Gaucher病に対する基質合成抑制療法		小児内科	東京医学社		平成30年	1557-1580
井田博幸	ライソゾーム病の基礎と臨床		医学のあゆみ	医歯薬出版(株)		平成30年	31-36
井田博幸	酵素補充療法の有効性と限界		日本臨床	日本臨床社		令和元年	1326-1331
井田博幸	リポドーシス		新臨床内科学第10版	医学書院		令和2年	780-784
井田博幸	先天代謝異常 Gaucher病		今日の小児治療指針 第17版	医学書院		令和2年	199-200
寒川真、楠 進。	補体を標的とした神経免疫疾患の新規治療	鈴木則宏 他	Annual Review 神経2019	中外医学社	東京	2019	113-122
楠 進	神経筋疾患における糖脂質抗体測定	鈴木則宏 他	Annual Review 神経2020	中外医学社	東京	2020	300-305
秋丸裕司、坂手龍一、吉野満昭、木村友則	指定難病の臨床調査個人票のデータベース活用	腎臓内科編集委員会	腎臓内科	科学評論社	日本	2020	12(5), 589-600
秋丸裕司、乾和歌子、村井英継	指定難病の臨床調査個人票とのデータベース連携	脳神経内科編集委員会	脳神経内科	科学評論社	日本	2020	92(3), 332-339

大竹 明	小児の難病と「ALA」	北尾吉孝+「ALAの未来」を考える会	ALAが創る未来。「生命の根源物質」でバイオと医療・健康に貢献する.	PHP研究所	東京	2020	177-199
村山 圭, 小坂 仁, 三牧 将和	ミトコンドリアと病気	村山 圭, 小坂 仁, 三牧 将和	遺伝医学MOOK	メディカルドゥ	東京	2020	172-176
村山 圭	ミトコンドリア異常症	水口 雅, 市橋 光, 崎山 弘, 伊藤 秀一	今日の小児診療指針	医学書院	東京	2020	194-195
山野嘉久.	HTLV-1関連脊髄症 (HAM) の新たな診察ガイドライン.	鈴木 則宏, 荒木 信, 宇川 義一, 桑原 聡, 塩川 崇	Annual Review 神経2020	中外医学社	東京	2020	131-136
山野嘉久, 他: 「HTLV-1関連脊髄症 (HAM) 診療ガイドライン2019」作成委員会.	HTLV-1関連脊髄症 (HAM) 診療ガイドライン2019.	「HTLV-1関連脊髄症 (HAM) 診療ガイドライン2019」作成委員会	HTLV-1関連脊髄症 (HAM) 診療ガイドライン2019.	南江堂	東京	2019	1-181
山野嘉久.	HTLV-1関連脊髄症 [指定難病26]	水澤英洋、五十嵐 隆、北川泰久、高橋和久、弓倉 整	指定難病ペディア2019	診断と治療社	東京	2019	95-97
山野嘉久.	HTLV-1関連脊髄症	南学正臣	内科学書 改訂第9版	中山書店	東京	2019	386-387
山野嘉久.	痙性対麻痺 (HAMを含む) .	福井次矢, 高木誠, 小室一成	今日の治療方針 2020年度版	医学書院	東京	2020	62: 980-981
山野嘉久.	HTLV-1関連脊髄症.	永井良三	今日の診断指針 第8版 ポケット判	医学書院	東京	2020	593-596
佐々木 秀直、渡辺宏久、下畑享良、日本神経学会運動失調症セクション	運動失調症の呼吸管理	小林弘祐	標準的医療説明の手順書	内科系学会社会保険料連合	東京	2019	128-133
佐藤晃一、原章規、和田隆志	腎臓障害に関連する指定難病の動向		腎臓内科	科学評論社	東京	2021	136-143

雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Hara A, Wada T, Sada KE, Amano K, Dobashi H, Harigai M, Takasaki Y, Yamada H, Hasegawa H, Hayashi T, Fujimoto S, Muso E, Kawakami T, Homma S, Yoshida M, Hirahashi J, Ogawa N, Ito S, Makino H, Arimura Y; Research Committee on Intractable Vasculitides and the Strategic Study Group to Establish the Evidence for Intractable Vasculitis Guideline.	Risk Factors for Relapse of Antineutrophil Cytoplasmic Antibody-associated Vasculitis in Japan: A Nationwide, Prospective Cohort Study.	J Rheumatol	45(4)	521-528	2018

<p>Yamamoto R, Imai E, Maruyama S, Yokoyama H, Sugiyama H, Nitta K, Tsukamoto T, Uchida S, Takeda A, Sato T, Wada T, Hayashi H, Akai Y, Fukunaga M, Tsunoda K, Masutani K, Koyama T, Shoji T, Hiramatsu T, Goto S, Tamai H, Nishio S, Shirasaki A, Nagai K, Yamagata K, Hasegawa H, Yasuda H, Ichida S, Naruse T, Fukami K, Nishino T, Sobajima H, Tanaka S, Akahori T, Ito T, Yoshio T, Katafuchi R, Fujimoto S, Okada H, Ishimura E, Kazama JJ, Hiromura K, Mimura T, Suzuki S, Saka Y, Sofue T, Suzuki Y, Shibagaki Y, Kitagawa K, Morozumi K, Fujita Y, Mizutani M, Shigematsu T, Kashihara N, Sato H, Matsuo S, Narita I, Isaka Y.</p>	<p>Regional variations in immunosuppressive therapy in patients with primary nephrotic syndrome: the Japan nephrotic syndrome cohort study.</p>	<p>Clin Exp Nephrol</p>	<p>22(6)</p>	<p>1266-1280</p>	<p>2018</p>
<p>Harigai M, Nagasaka K, Amano K, Bandoh M, Dobashi H, Kawakami T, Kishibe K, Murakawa Y, Usui J, Wada T, Tanaka E, Nango E, Nakayama T, Tsutsumino M, Yamagata K, Homma S, Arimura Y.</p>	<p>2017 Clinical practice guidelines of the Japan Research Committee of the Ministry of Health, Labour, and Welfare for Intractable Vasculitis for the management of ANCA-associated vasculitis.</p>	<p>Mod Rheumatol</p>	<p>29(1)</p>	<p>20-30</p>	<p>2018</p>

<p>Kanda E, Kashihara N, Matsushita K, Utsui T, Okada H, Isseki K, Mikami K, Tanaka T, Wada T, Watanabe H, Ueki K, Nishigaki M; Research Working Group for Establishing Guidelines for Clinical Evaluation of Chronic Kidney Disease.</p>	<p>Guidelines for clinical evaluation of chronic kidney disease : AMED research on regulatory science of pharmaceuticals and medical devices.</p>	<p>Clin Exp Nephrol</p>	<p>22(6)</p>	<p>1446-1475</p>	<p>2018</p>
<p>Kikuchi K, Saigusa D, Kanemitsu Y, Matsumoto Y, Thanai P, Suzuki N, Miskawa K, Yamaguchi H, Nakamura T, Asaji K, Mukawa C, Tsukamoto H, Sato T, Oikawa Y, Iwasaki T, Oe Y, Tsukimi T, Fukuda NN, Ho HJ, Nantoh-Hara F, Ogura J, Saito R, Nagao S, Ohsaki Y, Shimada S, Suzuki T, Toyohara T, Mishima E, Shima H, Akiyama Y, Akiyama Y, Ichijima M, Matsushashi T, Matsuo A, Ogata Y, Yang CC, Suzuki C, Breeggemann MC, Heymann J, Shimizu M, Ogawa S, Takahashi N, Suzuki T, Owada Y, Kure S, Mano N, Soga T, <u>Wada T</u>, Kopp JB, Fukuda S, Hozawa A, Yamamoto M, Ito S, Wada J, Tomioka Y, Abe T.</p>	<p>Gut microbiome-derived phenyl sulfate contributes to albuminuria in diabetic kidney disease.</p>	<p>Nat Commun</p>	<p>10(1)</p>	<p>1835</p>	<p>2019</p>

<p>Isobe M, Amano K, Arimura Y, Ishizu A, Ito S, Kaname S, Kobayashi S, Komagata Y, Komuro I, Komori K, Takahashi K, Tanemoto K, Hasegawa H, Harigami M, Fujimoto S, Miyazaki T, Miyata T, Yamada H, Yoshida A, <u>Wada T</u>, Inoue Y, Uchida A. H, Ota H, Okazaki T, Onimaru M, Kawakami T, Kinouchi R, Kurata A, Kosuge H, Sada K, Shigematsu K, Suematsu E, Sueyoshi E, Sugihara T, Sugiyama H, Takeno M, Tamura N, Tsubsumino M, Dobashi H, Nakaoka Y, Nagasaka K, Maejima Y, Yoshifuji H, Watanabe Y, Ozaki S, Kimura T, Shigematsu H, Yamauchi-Takahara K, Murohara T, Momomura S, on behalf of the JCS Joint Working Group</p>	<p>JCS 2017 Guideline on Management of Vasculitis Syndrome — Digest Version —</p>	<p>Circ J</p>	<p>84(2)</p>	<p>299-359</p>	<p>2020</p>
<p>Tran TTT, Hara A, Kitagawa K, Kitajima S, Toyama T, Iwata Y, Sakai N, Shimizu M, Kaneko S, Furuichi K, <u>Wada T</u>.</p>	<p>Relationship between autoantibodies to erythropoietin receptor and renal outcome in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis.</p>	<p>Biomarkers</p>	<p>25(2)</p>	<p>194-200</p>	<p>2020</p>

Yamamoto R, Imai E, Maruyama S, Yokoyama H, Sugiyama H, Nitta K, Tsukamoto T, Uchida S, Takeda A, Sato T, Wada T, Hayashi H, Akai Y, Fukunaga M, Tsunoda Y, Masutani K, Konda T, Shoji T, Hiramatsu T, Goto S, Tamai H, Nishio S, Shirasaki A, Nagai K, Yamagata K, Hasegawa H, Yasuda H, Ichida S, Naruse T, Nishino T, Sobajima H, Tanaka S, Akahori T, Ito T, Terada Y, Katafuchi R, Fujimoto S, Okada H, Ishimura E, Kazama JJ, Hiromura K, Mimura T, Suzuki S, Saka Y, Sofue T, Suzuki Y, Shibagaki Y, Kitagawa K, Morozumi K, Fujita Y, Mizutani M, Shigematsu T, Kashihara N, Sato H, Matsuo S, Narita I, Isaka Y.	Incidence of remission and relapse of proteinuria, end-stage kidney disease, mortality, and major outcomes in primary nephrotic syndrome: the Japan Nephrotic Syndrome Cohort Study (JNSCS).	Clin Exp Nephrol	24(6)	526-540	2020
北川清樹・和田隆志	血漿交換療法の適応と現状	日本医師会雑誌	148(3)	447-451	2019

<p>Yamamoto R, Imai E, Maruyama S, Yokoyama H, Sugiyama H, Nitta K, Tsukamoto T, Uchida S, Takeda A, Sato T, <u>Wada T</u>, Hayashi H, Akai Y, Fukunaga M, Tsuruya K, Masutani K, Konta T, Shoji T, Hiramatsu T, Goto S, Tamai H, Nishio S, Shirasaki A, Nagai K, Yamagata K, Hasegawa H, Yasuda H, Ichida S, Naruse T, Nishino T, Sobajima H, Tanaka S, Akahori T, Ito T, Terada Y, Katafuchi R, Fujimoto S, Okada H, Ishimura E, Kazama JJ, Hiromura K, Mimura T, Suzuki S, Saka Y, Sofue T, Suzuki Y, Shibagaki Y, Kitagawa K, Morozumi K, Fujita Y, Mizutani M, Shigematsu T, Kashihara N, Sato H, Matsuo S, Narita I, Isaka Y.</p>	<p>Incidence of remission and relapse of proteinuria, end-stage kidney disease, mortality, and major outcomes in primary nephrotic syndrome: the Japan Nephrotic Syndrome Cohort Study (JNSCS).</p>	<p>Clin Exp Nephrol</p>	<p>24(6)</p>	<p>526-540</p>	<p>2020</p>
<p>Nakagawa N, Sofue T, Kanda E, Nagasu H, Matsushita K, Nangaku M, Maruyama S, <u>Wada T</u>, Terada Y, Yamagata K, Narita I, Yanagita M, Sugiyama H, Shigematsu T, Ito T, Tamura K, Isaka Y, Okada H, Tsuruya K, Yokoyama H, Nakashima N, Kataoka H, Ohe K, Okada M, Kashihara N.</p>	<p>J-CKD-DB: a nationwide multicentre electronic health record-based chronic kidney disease database in Japan.</p>	<p>Sci Rep</p>	<p>10(1)</p>	<p>7351</p>	<p>2020</p>

Yokoyama H, Yamamoto R, Imai E, Maruyama S, Sugiyama H, Nitta K, Tsukamoto T, Uchida S, Takeda A, Sato T, Wada T, Hayashi H, Akai Y, Fukunaga M, Tsuruya K, Masutani K, Konta T, Shoji T, Hiramatsu T, Goto S, Tamai H, Nishio S, Shirasaki A, Nagai K, Yamagata K, Hasegawa H, Yasuda H, Ichida S, Naruse T, Fukami K, Nishino T, Sobajima H, Tanaka S, Akahori T, Ito T, Terada Y, Katafuchi R, Fujimoto S, Okada H, Ishimura E, Kazama JJ, Hiromura K, Mimura T, Suzuki S, Saka Y, Sofue T, Suzuki Y, Shibagaki Y, Kitagawa K, Morozumi K, Fujita Y, Mizutani M, Shigematsu T, Furuichi K, Fujimoto K, Kashihara N, Sato H, Matsuo S, Narita I, Isaka Y.	Better remission rates in elderly Japanese patients with primary membranous nephropathy in nationwide real-world practice: The Japan Nephrotic Syndrome Cohort Study (JN-SCS).	Clin Exp Nephrol	24(10)	893-909	2020
Takahashi-Kobayashi M, Usui J, Kaneko S, Sugiyama H, Naitta K, Wada T, Muroso E, Arimura Y, Makino H, Matsuo S, Yamagata K.	Age-dependent survival in rapidly progressive glomerulonephritis: A nationwide questionnaire survey from children to the elderly.	PLoS One	15(7)	e0236017	2020
Wallace Z, Zhang Y, Perugino CA, Nadeau R, Choi HK, Stone JH, ACR/EULAR IgG4 Classification Criteria Committee. Clinical phenotypes of IgG4-related disease	An analysis of two international cross-sectional cohorts.	Annals Rheum Dis	78(3)	406-412	2019

<p>Nakamura T, Satoh- Nakamura T, Nakaji ma A, Kawanami T, Sakai T, Fujita Y, Iwao H, Miki M, Ma saki Y, Okazaki T, Ishigaki Y, Kawano M, Yamada K, Matsu i S, Saeki T, Kami sawa T, Yamamoto M, Hamano H, Origuch i T, Hirata S, Tan aka Y, Tsuboi H, S umida T, Okazaki K, Tanaka M, <u>Chiba T</u>, Mimori T, Umehara T</p>	<p>Impaired expression of innate immunity-related genes in IgG4-related disease: A possible mechanism in the pathogenesis of IgG4-RD.</p>	<p>Modern Rheumatology</p>	<p>11</p>	<p>1-7</p>	<p>2019</p>
<p>Terao C, Ota M, Iwasaki T, Shiokawa M, Kawaguchi S, Kuriyama K, Kawaguchi T, Kodama Y, Yamaguchi I, Uchida K, Higasa K, Yamamoto M, Kubota K, Yazumi S, Hirano K, Masaki Y, Maguchi H, Origuchi T, Matsui S, Nakazawa T, Shiohara H, Kamisawa T, Hasebe O, Iwasaki E, Inui K, Tanaka Y, Ohshima K, Akamizu T, Nakamura S, Saeki T, Umehara H, Shimosegawa T, Mizuno N, Kawano M, Azumi A, Takahashi H, Mimori T, Kamatani Y, Okazaki K, <u>Chiba T</u>, Kawa S, Matsuda F</p>	<p>IgG4-related disease in the Japanese population: a genome-wide association study.</p>	<p>Lancet Rheumatology</p>	<p>1(1)</p>	<p>14-22</p>	<p>2019</p>
<p>Niwamoto T, Handa T, Matsui S, Yamamoto H, Yoshifuji H, Abe H, Matsumoto H, Kodama Y, <u>Chiba T</u>, Seno H, Mimori T, Hirai</p>	<p>Phenotyping of IgG4-related diseases based on affected organ pattern: A multicenter cohort study using cluster analysis.</p>	<p>Modern Rheumatology</p>	<p>4</p>	<p>1-6</p>	<p>2020</p>

<p>Kakiuchi N, Yoshida K, Uchino M, Kihara T, Akaki K, Iinoue Y, Kawada K, Nagayama S, Yokoyama A, Yamamoto S, Matsuura M, Horimatsu T, Hirano T, Goto N, Takeuchi Y, Ochi Y, Shiozawa Y, Kogure Y, Watatani Y, Fujii Y, Kim SK, Kon A, Kataoka K, Yoshizato T, Nakagawa M, Yoda A, Nanya Y, Makishima H, Shiraiishi Y, Chiba K, Tanaka H, Sanada M, Sugihara E, Sato T, Maruyama T, Miyoshi H, Takeuchi MM, Oishi J, Inagaki R, Ueda Y, Okamoto S, Okajima H, Sakai Y, Sakurai T, Haga H, Hirota S, Ikeuchi H, Nakase H, Marusawa H, <u>Chiba T</u>, Takeuchi O, Miyano S, Seno H, Ogawa</p>	<p>Frequent mutations that converge on the NFKBIZ pathway in ulcerative colitis.</p>	<p>Nature</p>	<p>577(7789)</p>	<p>260-265</p>	<p>2020</p>
<p>Zhu Y, Cui G, Miyachi E, Nakanishi Y, Mukohira H, Shimba A, Abe S, Taniguchi S, Hara T, Nishikase H, <u>Chiba T</u>, Sehara-Fujisawa A, Seno H, Ohono H, Ikuta K.</p>	<p>Intestinal epithelial cell-derived IL-15 determines local maintenance and maturation of intraepithelial lymphocytes in the intestine.</p>	<p>Int Immunol</p>	<p>32(5)</p>	<p>307-319</p>	<p>2020</p>
<p>Shiokawa M, Kodama Y, <u>Chiba T</u></p>	<p>Different frequencies of antibody responses in IgG4-related disease.</p>	<p>Arthritis Rheumatol</p>	<p>72(9)</p>	<p>1584-1585</p>	<p>2020</p>

Sankoda N, Tanabe W, Tanaka A, Shibata H, Woltjen K, Chiba T, Haga H, Sakai Y, Mandai M, Yamamoto T, Yamada Y, Uemoto S, Kawaguchi Y	Epithelial expression of Gata 4 and Sox2 regulate Cs specification of the squamous-columnar junction in mice.	Nat Commun	12(1)	560	2021
Niwamoto T, Handa T, Matsui S, Yamamoto H, Yoshifuji H, Abe H, Matsumoto H, Kodama Y, Chiba T, Seno H, Mimori T, Hirai	Phenotyping of IgG4-related diseases based on affected organ pattern: A multicenter cohort study using cluster analysis.	Modern Rheumatol	31(1)	235-240	2021
Yamaguchi I, Furusawa Y, Kawaguchi T, Yagishita N, Tanzawa K, Yamano Y, Matsuda F	Establishment of a Comprehensive Information Infrastructure and a Support Organization for Rare Disease Research in Japan (RADDAR-J).	Stud Health Technol Inform	264	1080-1083	2019
Hiroo Hoshina, Yohta Shimada, Takashi Higuchi, Hiroshi Kobayashi, Hiroyuki Ida, Toya Ohashi.	Chaperone effect of sulfated disaccharide from heparin on mutant iduronate-2-sulfatase in mucopolysaccharidosis type II	Molecular Genetics and Metabolism	123	118-122	2018
Kobayashi M, Ohashi T, Kaneshiro E, Higuchi T, Ida H.	Mutation spectrum of α -galactosidase A gene in Japanese patients with Fabry disease.	J Hum Genet	64	695-699	2019
Hiroyuki Ida	Gaucher Disease.	Human Pathology biochemistry eds.		57-66	2019
Nojiri A, Anan I, Morimoto S, Kawai M, Sakuma T, Kobayashi M, Kobayashi H, Ida H, et al	Clinical findings of gadolinium-enhanced cardiac magnetic resonance in Fabry patients.	J Cardiol.	75	27-33	2020
Miwa S, Watabe A, Shimada Y, Higuchi T, Kobayashi H, Fukuda T, Kato F, Ida H, et al	Efficient engraftment of genetically modified cells is necessary to ameliorate central nervous system involvement of murine model of mucopolysaccharidosis type II by hematopoietic stem cell targeted gene therapy.	Mol Genet Metab.	130	262-273	2020

Wada M, Shimada Y, Izuka S, Ishii N, Hiraki H, Tachibana T, Maeda K, Saito M, Arakawa S, Ishimoto T, Ida H, et al	Ex vivo gene therapy treats bone complications of type II mouse models through bone remodeling reactivation.	Mol Ther Methods Clin Dev.	19	261-274	2020
Kuwahara M, Suzuki H, Oka N, Ogata H, Yanagimoto S, Sadakane S, Fukumoto Y, Yamana M, Yuhara Y, Yoshikawa K, Morikawa M, Kawai S, Okazaki M, Tsujimoto T, Kira JI, <u>Kusunoki S.</u>	Electron microscopic abnormality and therapeutic efficacy in chronic inflammatory demyelinating polyneuropathy with anti-neurofascin155 immunoglobulin G4 antibody	Muscle Nerve	57	498-502	2018
Miyamoto K, Fujiwara K, Kira JI, Kurayama N, Matsui M, Tamakoshi A, <u>Kusunoki S.</u>	Nationwide epidemiological study of neuromyelitis optica in Japan.	J Neurol Neurosurg Psychiatry	89	667-668	2018
Yoshikawa K, Kuwahara M, Morikawa M, Fukumoto Y, Yamana M, Yamagishi Y, <u>Kusunoki S.</u>	Varied antibody reactivities and clinical relevance in anti-GQ1b antibody-related diseases.	Neurol Neuroimmunol Neuroinflamm	5	e501	2018
Kuwahara M, Numoto I, <u>Kusunoki S</u>	Multifocal nodular hypertrophy of trigeminal nerve in multifocal acquired demyelinating sensory and motor neuropathy.	Neurol Neuroimmunol Neuroinflamm	6	e553	2019
Hirano M, Isono C, Fukuda K, Ueno S, Nakamura Y, <u>Kusunoki S</u>	Effects of the rotigotine transdermal patch versus oral levodopa on swallowing in patients with Parkinson's disease	J Neurol Sci	404	5-10	2019
Yoshikawa K, Kuwahara M, Morikawa M, <u>Kusunoki S.</u>	Bickerstaff brainstem encephalitis with or without anti-GQ1b antibody.	Neurol Neuroimmunol Neuroinflamm	7 (6)	e889	2020

Yamagishi Y, Kuwahara M, Suzuki H, Sano M, Kuwabara S, Yokota T, Nomura K, Chiba A, Kaji R, Kanda T, Kaida KI, Mutoh T, Yamasaki R, Takashima H, Matsui M, Nishiyama K, Sobue G, Kusunoki S.	Serum IgG anti-GD1a antibody and mEGOS predict outcome in Guillain-Barré syndrome.	J Neurol Neurosurg Psychiatry	91(12)	1339-1342	2020
Kusunoki S	CSF sphingomyelin: possible biomarker of demyelination.	J Neurol Neurosurg Psychiatry.	92(3)	232	2021
Kusunoki S, Willison HJ, Jacobs BC	Antiglycolipid antibodies in Guillain-Barré and Fisher syndromes: discovery, current status and future perspective	J Neurol Neurosurg Psychiatry	92(3)	311-318	2021
Watanabe M, Nishikawa H, <u>Miyasaka N</u> , Sato R, Sato D, Hayashi Y, Kondo T.	Adverse Drug Reaction Relief System in Japan: From Clinical Perspective	Ther Innov Regul Sci	Jul ; 54(4):	731-737	2020
Hosoya T, Sugihara T, <u>Miyasaka N</u> , Yasuda S.	Novel treatment strategy of polymyalgia rheumatica targeting drug-free remission	Clin Exp Rheumatol	PMID: 33253104		2020
Kaneko Y, Kawahito Y, Kojima M, Nakayama T, Hirata S, Kishimoto M, Endo H, Seto Y, Ito H, Nishida K, Matsushita I, Kojima T, Kamatani N, Tsutani K, Igarashi A, Hasegawa M, <u>Miyasaka N</u> , Yamanaka H.	Efficacy and safety of tocilizumab in patients with rheumatoid arthritis - A systematic review and meta-analysis.	Mod Rheumatol.	30	1-9. doi: 10.1080/14397595.2020.1719607. [Epub ahead of print]	2020
Tanaka Y, Atsumi T, Yamamoto K, Takeuchi T, Yamanaka H, Ishiguro N, Eguchi K, Watanabe A, Otagasa H, Shoji T, <u>Miyasaka N</u> , Koike T.	Factors associated with successful discontinuation of certolizumab pegol in early rheumatoid arthritis.	Int J Rheumatol Dis.	23(3)	316-324. doi: 10.1111/1756-185X.13780. Epub 2020 Jan 19.	2020

Tanaka Y, Oba K, Koike T, <u>Miyasaka N</u> , Mimori T, Takeuchi T, Hirata S, Tanaka E, Yasuoka H, Kaneko Y, Murakami K, Koga T, Nakano K, Amano K, Ushio K, Atsumi T, Inoo M, Hatta K, Mizuki S, Nagaoka S, Tsunoda S, Dobashi H, Horie N, Sato N.	Sustained discontinuation of infliximab with a raising-dose strategy after obtaining remission in patients with rheumatoid arthritis: the RRRR study, a randomised controlled trial.	Ann Rheum Dis	79(1)	94-102. doi: 10.1136/annrheumdis-2019-216169. Epub 2019 Oct 19.	2019
Kojima M, Nakayama T, Tsutani K, Igarashi A, Kojima T, Suzuki S, <u>Miyasaka N</u> , Yamanaka H.	Epidemiological characteristics of rheumatoid arthritis in Japan: Prevalence estimates using a nationwide population-based questionnaire survey.	Mod Rheumatol.	14	1-7. doi: 10.1080/14397595.2019.1682776. [Epub ahead of print]	2019
Takada K, Katada Y, Ito S, Hayashi T, Kishi J, Itoh K, Yamashita H, Hirakata M, Kawahata K, Kawakami A, Watanabe N, Atsumi T, Takasaki Y, <u>Miyasaka N</u> .	Impact of adding tacrolimus to initial treatment of interstitial pneumonitis in polymyositis/dermatomyositis: a single-arm clinical trial.	Rheumatology (Oxford).	pii: kez394. doi: 10.1093/rheumatology/kez394. [Epub ahead of print]		2019
Miyabe C, Miyabe Y, Nagai J, Miura NN, Ohno N, Chun J, Tsuboi R, Ueda H, <u>Miyasaka M</u> , <u>Miyasaka N</u> , Nanki T.	Abrogation of lysophosphatidic acid receptor 1 ameliorates murine vasculitis.	Arthritis Res Ther.	21(1)	191. doi: 10.1186/s13075-019-1973-0.	2019
Kato M, Kaneko Y, Tanaka Y, Inoo M, Kobayashi-Haraoka H, Amano K, Miyata M, Murakawa Y, Yasuoka H, Hirata S, Nagasawa H, Tanaka E, <u>Miyasaka N</u> , Yamanaka H, Yamamoto K, Yokota I, Atsumi T, Takeuchi T.	Predictive value of serum amyloid A levels for requirement of concomitant methotrexate in tocilizumab initiation: A post hoc analysis of the SURPRISE study.	Mod Rheumatol.	7	1-8. doi: 10.1080/14397595.2019.1621026. [Epub ahead of print]	2019

Takeuchi T, Miyasaka N, Pedersen R, Sugiyama N, Hirose T.	Radiographic and clinical outcomes following etanercept monotherapy in Japanese methotrexate-naïve patients with active rheumatoid arthritis.	Mod Rheumatol.	30(2)	259-268. doi: 10.1080/14397595.2019.1589918. Epub 2019 Mar 29.	2019
Kasai S, Sakai R, Koike R, Kohsaka H, Miyasaka N, Harigai M.	Higher risk of hospitalized infection, cardiovascular disease, and fracture in patients with rheumatoid arthritis determined using the Japanese health insurance database.	Mod Rheumatol.	29(5)	788-794. doi: 10.1080/14397595.2018.1519889. Epub 2018 Nov 28.	2019
Yamanaka H, Hirose T, Endo Y, Sugiyama N, Fukuma Y, Morishima Y, Sugiyama N, Yoshii N, Miyasaka N, Koike T.	Three-year safety and two-year effectiveness of etanercept in patients with rheumatoid arthritis in Japan: Results of long-term postmarketing surveillance.	Mod Rheumatol.	29(5)	737-746. doi: 10.1080/14397595.2018.1510759. Epub 2018 Sep 20.	2019
Kaneko Y, Kato M, Tanaka Y, Inoue M, Kobayashi-Haraoka H, Amano K, Miyata M, Murakawa Y, Yasuoka H, Hirata S, Tanaka E, Miyasaka N, Yamanaka H, Yamamoto K, Takeuchi T, SURPRISE study group	Tocilizumab discontinuation after attaining remission in patients with rheumatoid arthritis who were treated with tocilizumab alone or in combination with methotrexate: results from a prospective randomised controlled study (the second year of the SURPRISE study)	Ann Rheum Dis	Sep;77(9)	1268-1275	2018
Umezawa, N, Kwahata K, Mizoguchi F, Kimura N, Yoshihashi-Nakazato Y, Miyasaka N, Kohsaka H.	Interleukin-23 as a therapeutic target for inflammatory myopathy	Sci Rep	Apr 3;8(1)	doi: 10.1038/s41598-018-23539-4.	2018
Wolfien M. et. al	Hematopoietic stem-cell senescence and myocardial repair - Coronary artery disease genotype/phenotype analysis of post-MI myocardial regeneration response induced by CABG/CD133+ bone marrow hematopoietic stem cell treatment in RCT PERFECT Phase 3.	EBioMedicine	57	102862	2020

Akiyama N, Shimura M, Yamazaki T, Harashima H, Fushimi T, Tsuruoka T, Ebihara T, Ichimoto K, Matsunaga A, Saito-Tsuruoka M, Yatsuka Y, Kishita Y, Kohda M, Namba A, Kamei Y, Okazaki Y, Kosugi A, Ohtake A, Murayama K	Prenatal diagnosis of severe mitochondrial diseases caused by nuclear gene defects: a study in Japan.	Sci Rep	11(1)	3531	2021
Koshizaka M, Maezawa Y, Maeda Y, Shoji M, Kato H, Kaneko H, Ishikawa T, Kinoshita D, Kobayashi K, Kawashima J, Sekiguchi A, Motegi SI, Nakagami H, Yamada Y, Tsukamoto S, Taniguchi A, Sugimoto K, Shoda Y, Hashimoto K, Yoshimura T, Suzuki D, Kuzuya M, Takemoto M, Yokote K.	Time gap between the onset and diagnosis in Werner syndrome: a nationwide survey and the 2020 registry in Japan	Aging (Albany NY)	12	24940-24956	2020
村山圭	ミトコンドリア病	特殊ミルク治療ガイドブック	24	71-73	2020
村山圭	先天代謝異常症	今日の診断指針	第8版総	1918-1920	2020
村山圭	カルニチン回路異常症	新臨床内科学	第10版第6章	784-786	2020
杉山洋平、村山圭	新生児期に緊急対応が必要な先天代謝異常症	新生児内分泌ハンドブック	新版 7代	213-225	2020
盛一享徳	小児疾患の医療費助成制度	小児外科	53(3)	249-51	2021
盛一享徳	小児慢性特定疾病と指定難病	Modern Media	66(3)	68-73	2020

Nagasaka M, Yamagishi M, Yagishita N, Araya N, Kobayashi S, Makiyama J, Kubokawa M, Yamauchi J, Hasegawa D, Collier-Reilly ALG, Tsutsumi S, Uemura Y, Arai A, Takata A, Inoue E, Hasegawa Y, Watanabe T, Suzuki Y, Uchimaru K, Sato T, Yamano Y.	Mortality and risk of progression to adult T-cell leukemia/lymphoma in HTLV-1-associated myelopathy/tropical spastic paraparesis.	Proc Natl Acad Sci U S A	117(21)	11685-11691	2020
Yamauchi J, Araya N, Yagishita N, Saito T, Yamano Y.	An update on human T-cell leukemia virus type 1 (HTLV-1)-associated myelopathy/tropical spastic paraparesis (HAM/TSP) focusing on clinical and laboratory biomarkers.	Pharmacol Ther	218	107669	2021
Yamakawa N, Yagishita N, Matsuo T, Yamauchi J, Ueno T, Inoue E, Takata A, Nagasaka M, Araya N, Hasegawa D, Collier-Reilly A, Tsutsumi S, Sato T, Araujo A, Casseb J, Gotuzzo E, Jacobson S, Martin F, Puccioni-Sohler M, Taylor GP, Yamano Y; Japan Clinical Research Group on HAM/TSP.	Creation and validation of a bladder dysfunction symptom score for HTLV-1-associated myelopathy/tropical spastic paraparesis.	Orphanet J Rare Dis	15(1)	175	2020
Kamoi K, Horiguchi N, Kurozumi-Karube H, Hamaguchi I, Yamano Y, Uchimaru K, Tojo A, Watanabe T, Ohno-otsui K.	Horizontal transmission route responsible for human T-cell lymphotropic virus type 1 uveitis.	Lancet Infect Dis	in press		2021

Penova M, Kawaguchi S, Yasunaga J, Kawaguchi T, Sato T, Takahashi M, Shimizu M, Saito M, Tsukasaki K, Nakagawa M, Takenouchi N, Hara H, Matsuura E, Nozuma S, Takashima H, Izumo S, Watanabe T, Uchimaru K, Iwanaga M, Utsunomiya A, Tabara Y, Paul R, Yamano Y, Matsuoka M, Matsuda F.	Genome wide association study of HTLV-1-associated myelopathy/tropical spastic paraparesis in the Japanese population.	Proc Natl Acad Sci USA	118(11)	e2004199118	2021
Takeda R, Ishigaki T, Ohno N, Yokoyama K, Kawamata T, Fukuyama T, Araya N, Yamano Y, Uchimaru K, Tojo A.	Immunophenotypic analysis of cerebrospinal fluid reveals concurrent development of ATL in the CNS of a HAM/TSP patient.	Int J Hematol	111(6)	891-896	2020
Hagiwara Y, Shimizu T, Yanagisawa T, Akasu Y, Kaburagi K, Kikuchi T, Shibata S, Matsumoto H, Soga K, Tsuchihashi Y, Nagasaka M, Sasaki N, Maki F, Shiraishi M, Akiyama H, Hasegawa Y, Yamano Y.	Utility of transoral motion-mode ultrasonography to detect tongue fasciculation in patients with amyotrophic lateral sclerosis.	Muscle Nerve	Online ahead of print		2021
Araujo A, Bangham CRM, Casseb J, Gotuzzo E, Jacobson S, Martin F, Penalva A, Puccioni-Sohler M, Taylor GP, Yamano Y.	Management of HAM/TSP. systematic review and consensus-based recommendations 2019.	Neurol Clin Pract	11(1)	49-56	2021

Okuma K, Kuramitsu M, Niwa T, Taniguchi T, Masaki Y, Ueda G, Matsumoto C, Sobata R, Sagara Y, Nakamura H, Satake M, Miura K, Fuchii N, Masuzaki H, Okayama A, Umeki K, Yamano Y, Sato T, Iwanaga M, Uchimarui K, Nakashima M, Utsunomiya A, Kubota R, Ishitsuka K, Hasegawa H, Sasaki D, Koh KR, Taki M, Nosaka K, Ogata M, Naruse I, Kaneko N, Okajima S, Tezuka K, Ikebe E, Matsuo ka S, Itabashi K, Saito S, Watanabe T, Hamaguchi I.	Establishment of a novel diagnostic test algorithm for human T-cell leukemia virus type 1 infection with line immunoassay replacement of western blotting: a collaborative study for performance evaluation of diagnostic assays in Japan,	Retrovirology	17	26	2020
Sakamoto H, Itonaga H, Sawayama Y, Kitajima A, Chiwata M, Fujioka M, Kitano-sono H, Horai M, Miyazaki T, Shiraishi H, Imaizumi Y, Yoshida S, Hata T, Yamano Y, Miyazaki Y.	Allogeneic Hematopoietic Stem Cell Transplantation for Adult T-cell Leukemia/Lymphoma with HTLV-1-associated Myelopathy.	Int J Hematol	Online ahead of print		2021
Soga K, Shimizu T, Hagiwara Y, Ogura H, Akiyama H, Yamuchi J, Sato T, Hanzawa K, Hasegawa Y, Yamano Y.	Soleal vein dilatation in the early-phase of hospitalization is associated with a subsequent development of deep vein thrombosis in patients with acute stroke.	J Med Ultrason(2001)	48(1)	97-104	2021
Tsuchihashi Y, Shimizu T, Akiyama H, Hagiwara Y, Soga K, Takao N, Uchino K, Yanagisawa T, Yamuchi J, Sato T, Hasegawa Y, Yamano Y.	The Risk Factors for Death within 6 Months After Ischemic Stroke in Patients with Cancer.	J Stroke Cerebrovasc Dis	29(12)	105365	2020

Takao N, Hagiwara Y, Shimizu T, Soga K, Tsuchihashi Y, Otsubo H, Tatsuno K, Takaishi S, Usuki N, Yoshie T, Takada T, Hasegawa Y, Yamano Y.	Preprocedural Carotid Plaque Echolucency as a Predictor of In-Stent Intimal Restenosis after Carotid Artery Stenting.	J Stroke Cerebrovasc Dis	29(12)	105339	2020
Shimizu J, Yamano Y, Kawahata K, Suzuki N.	Elucidation of predictors of disease progression in patients with relapsing polychondritis at the onset: potential impact on patient monitoring.	BMC Rheumatol	4	41	2020
Sakurai K, Shinohara K, Imai T, Yamano Y, Hasegawa Y.	A Case of Severe Multiple Sclerosis Manifesting upon GnRH Agonist Therapy for Uterine Fibroids: A Case Report.	Intern Med	59(23)	3093-3096	2020
山野嘉久.	HTLV-1関連脊髄症 (HAM) に対する分子標的治療薬.	脳神経疾患 最新の治療	2021-2023	32-34	2021
山野嘉久.	HTLV-1関連脊髄症 (HAM) の研究進展からみえる診療の未来像.	SRL宝函	41(3)	21-30	2020
山野嘉久.	HAM/TSPの診断指針 HTLV-1関連脊髄症 (HAM) 診察ガイドライン2019を踏まえて.	脊柱脊髄ジャーナル	33(4)	498-503	2020
佐藤知雄, 山野嘉久.	免疫性神経疾患 update — 基礎・臨床研究の最新知見 — HAMに対する治療薬の現状と展望.	日本臨床	78(11)	1939-1944	2020
新谷奈津美, 山野嘉久.	HTLV-1関連脊髄症 (HAM) の病態.	別冊BIO Clinica 神経疾患と慢性炎症	9(2)	29-33	2020
山内淳司, 山野嘉久, 湯沢賢治.	臓器移植におけるHTLV-1感染への対応.	日本臨床腎移植学会雑誌	8(1)	42-51	2020
山内淳司, 山野嘉久.	HTLV-1関連脊髄症 (HAM) の発症メカニズム.	周産期医学	50(10)	1695-1698	2020
山内淳司, 山野嘉久.	HTLV-1関連脊髄症.	CLINICAL NEUROSCIENCE	38(10)	1270-1271	2020
八木下尚子, 山野嘉久.	HTLV-1関連脊髄症.	生体の科学	71(5)	422-423	2020

鈴木祐, 秋山久尚, 星野俊, 鹿島悟, 原大祐, 土橋瑤子, 伊佐早健司, 櫻井謙三, 眞木二葉, 長谷川泰弘, 山野嘉久.	院内発症脳卒中の診断・治療遅延因子.	脳卒中	in press		2020
曾我海馬, 清水高弘, 飯島直樹, 鷹尾直誠, 土橋瑤子, 柴田宗一郎, 小倉英, 萩原悠太, 栗田千尋, 佐々木直, 秋山久尚, 長谷川泰弘, 山野嘉久.	頸動脈狭窄患者において血清MMP-9濃度は頭蓋内主幹動脈狭窄リスクと関連する.	聖マリアンナ医科大学雑誌	48(3)	101-108	2020
鷹尾直誠, 櫻井謙三, 日野栄絵, 山野嘉久.	再発性細菌性髄膜炎の原因として鼻汁を契機に鼻性髄液漏の診断に至った1例.	臨床神経	61(3)	177-181	2021
萩原悠太, 菊池崇之, 赤須友香利, 松本博文, 鏑木圭, 柴田宗一郎, 笹野恭之, 齋藤善光, 清水高弘, 山野嘉久.	扁桃周囲膿瘍に対する経口腔咽頭超音波ガイド下排膿穿刺術—経口腔頸動脈超音波の応用—.	Neurosonology	33(2)	45-49	2020
Yamauchi J, Sato T, Yagishita N, Araya N, Hasegawa D, Tasutsumi S, Nagasaka M, Coler-Reilly A, Inoue E, Takata A, Hasegawa Y, Yamano Y.	Use of cerebrospinal fluid CXCL10 and neopterin as biomarkers in HTLV-1-associated myelopathy/tropical spastic paraparesis treated with steroids.	J Neurol Neurosurg Psychiatry	91(3)	321-323	2020
Tsutsumi S, Sato T, Yagishita N, Yamauchi J, Araya N, Hasegawa D, Nagasaka M, Coler-Reilly A, Inoue E, Takata A, Yamano Y.	Real-World Clinical Course of HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP) in Japan.	Orphanet Journal of Rare Diseases	14(1)	227	2019

Katsuya H, Islam S, Tan BJY, Ito J, Miyazato P, Matsuo M, Inada Y, Iwase M, Uchiyama Y, Hata H, Sato T, Yagishita N, Araya N, Ueno T, Nosaka K, Tokunaga M, Yamagishi M, Watanabe T, Uchimaru K, Fujisawa JI, Utsunomiya A, Yamano Y, Satou Y.	The Nature of the HTLV-1 Provirus in Naturally Infected Individuals Analyzed by the Viral DNA-Capture-Seq Approach.	Cell Rep	29(3)	724-735. e4	2019
Tamaki K, Sato T, Tsugawa J, Fujioka S, Yagishita N, Araya N, Yamauchi J, Coler-Reilly A, Nagasaka M, Hasegawa Y, Yamano Y, Tsuboi Y.	Cerebrospinal Fluid CXCL10 as a Candidate Surrogate Marker for HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis.	Front Microbiol	10	2110	2019
Yamaguchi I, Furusawa Y, Kawaguchi T, Yagishita N, Tanzawa K, Yamano Y, Matsuda F.	Establishment of a Comprehensive Information Infrastructure and a Support Organization for Rare Disease Research in Japan (RADDAR-I).	Stud Health Technol Inform	264	1080-1083	2019
山内淳司, 山野嘉久, 湯沢賢治.	腎移植におけるHTLV-1感染のリスク.	移植	54(6)	305-307	2019
山内淳司, 山野嘉久.	HAMの病態とHTLV-1感染細胞の異常.	細胞	51(10)	20-23	2019
山野嘉久.	HTLV-1.	産科と婦人科 増刊号	87	25-28	2020
八木下尚子, 山野嘉久.	患者レジストリの分類.	脳神経内科	92(3)	271-275	2020
Sato T, Coler-Reilly ALG, Yagishita N, Araya N, Inoue E, Furuta R, Watanabe T, Uchimaru K, Matsuoka M, Matsumoto N, Hasegawa Y, Yamano Y.	Mogamulizumab (Anti-CCR4) in HTLV-1-Associated Myelopathy.	N Engl J Med	378(6)	529-538	2018
Yamauchi J, Yamano Y, Yuzawa K.	Risk of Human T-cell Leukemia Virus Type 1 Infection in Kidney Transplantation.	N Engl J Med	380(3)	296-298	2019

Sato T, Yagishita N, Tamaki K, Inoue E, Hasegawa D, Nagasaka M, Suzuki H, Araya N, Coler-Reilly AL, Hasegawa Y, Tsuboi Y, Takata A, Yamano Y.	Proposal of Classification Criteria for HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis Disease Activity.	Front Microbiol	9	1651	2018
Furusawa Y, Yamaguchi I, Yagishita N, Tanzawa K, Matsuda F, Yamano Y, RADAR - J Research and Development Group.	National platform for Rare Diseases Data Registry of Japan.	Learning Health Systems		e10080	2019
Oka T, Mizuno H, Sakata M, Fujita H, Yoshino T, Yamano Y, Utsumi K, Masujima T, Utsunomiya A.	Metabolic abnormalities in adult T-cell leukemia/lymphoma and induction of specific leukemic cell death using photodynamic therapy.	Sci Rep	8(1)	14979	2018
Kuramitsu M, Okuma K, Nakashima M, Saito T, Sasaki D, Hasegawa H, Umeki K, Kubota R, Sasada K, Sobata R, Matsumoto C, Kaneko N, Tezuka K, Matsuoka S, Utsunomiya A, Kohno K, Ogata M, Ishitaka K, Taki M, Nosaka K, Uchimaru K, Iwanaga M, Sagara Y, Yamano Y, Okayama A, Miura K, Satake M, Saito S, Watanabe T, Hamaguchi I.	Development of reference material with assigned value for human T-cell leukemia virus type 1 quantitative PCR in Japan.	Microbiol Immunol	62(10)	673-676	2018

Kawano N, Yoshida S, Kawano S, Kuriyama T, Tahara Y, Toyofuku A, Manabe T, Doi A, Terasaka S, Yamashita K, Ueda Y, Ochiai H, Marutsuka K, Yamano Y, Shimoda K, Kikuchi I.	The clinical impact of human T-lymphotropic virus type 1 (HTLV-1) infection on the development of adult T-cell leukemia-lymphoma (ATL) or HTLV-1-associated myelopathy (HAM) / atypical HAM after allogeneic hematopoietic stem cell transplantation (allo-HSCT) and renal transplantation: 11 years of experience.	J Clin Exp Hematop	58(3)	107-121	2018
Shimizu J, Yamano Y, Kawahata K, Suzuki N.	Relapsing polychondritis patients were divided into three subgroups: patients with respiratory involvement (R subgroup), patients with auricular involvement (A subgroup), and overlapping patients with both involvements (O subgroup), and each group had distinctive clinical characteristics.	Medicine	97(42)	e12837	2018
Morio Y, Izawa KP, Omori Y, Katata H, Ishiyama D, Koyama S and Yamano Y.	The relationship between walking speed and step length in older aged patients.	Diseases.	7(1)	7	2019
Hirano M, Jimbo K, Ogawa M, Ochi K, Miyakiyama J, Kawamata T, Yokoyama K, Tanaka T, Inamoto Y, Yamano Y, Fukuda T, Uchimaru K, Imai Y, Tojo A.	Chronic inflammatory demyelinating polyneuropathy in adult T-cell leukemia-lymphoma patients following allogeneic stem cell transplantation Bone Marrow Transplantation.	Bone Marrow Transplantation	53	1470- 1473	2018
Sato T, Yamano Y.	Targeting human T - lymphotropic virus type 1 - infected cells with an anti - C - C chemokine receptor 4 antibody in T - lymphotropic virus type 1 - associated myelopathy.	Clin Exp Neuroimmunol	9(3)	153-154	2018

八木下尚子, 山野嘉久.	希少難病HAMの患者レジストリを活用した治療薬開発への取り組みと展望.	Jpn Pharmacol Ther (薬理と治療)	46(7)	1113-1116	2018
森尾裕志, 大森圭貢, 井澤和大, 堅田紘頌, 石山大介, 小山真吾, 中尾陽光, 山野嘉久.	高齢入院患者におけるペットボトルの開栓に必要な握力.	専門リハビリ	17	30-35	2018
Koshizaka M, Maezawa Y, Maeda Y, Shoetsu M, Kato H, Kaneko H, Ishikawa T, Kinoshita D, Kobayashi K, Kawashima J, Sekiguchi A, Motegi SI, Nakagami H, Yamada Y, Tsukamoto S, Taniguchi A, Sugimoto K, Shoda Y, Hashimoto K, Yoshimura T, Suzuki D, Kuzuya M, Takemoto M, Yokote K.	Time gap between the onset and diagnosis in Werner syndrome: a nationwide survey and the 2020 registry in Japan	Aging (Albany NY)	12	24940-24956	2020
Shibata Y, Yabe I, Matsushima M, Hashimoto N, Yamada T, Sasaki H.	Investigating the role of genetic counseling in neuromuscular disease considering life events	J Hum Genet	64(6)	551-559	2019
佐々木秀直, 水澤英洋	国際コンセンサス基準とその問題点	Clinical Neuroscience	37(9)	1110-1112	2019
佐々木秀直, 運動失調症の医療基盤に関する調査研究班MSA分科会	わが国の指定難病の診断基準(案)- 現行基準の課題と展望	Clinical Neuroscience	37(9)	1113-1116	2019
Uwatoko H, Hama Y, Iwata IT, Shirai S, Matsushima M, Yabe I, Utsumi J, Sasaki H.	Identification of plasma microRNA expression changes in multiple system atrophy and Parkinson's disease	Mol Brain	12(1)	e49	2019

Naganuma R, Yabe I, Takeuchi M, Morishita K, Nakane S, Takase R, Takahashi-Iwata I, Matsushima M, Otsuki M, Shiraishi H, Sasaki H.	Clinical factors affecting evoked magnetic fields in patients with Parkinson's disease	Plos One	15(9)	e0232808	2020
Eguchi K, Tsuzaka K, Yabe I, Sasaki H.	Reversible splenic lesion in new-onset refractory status epilepticus: A case report	Clin Neurol Neurosurg	183	105392	2019
Shirai S, Yabe I, Takahashi-Iwata I, Matsushima M, Ito YM, Takakusaki K, Sasaki H.	The responsiveness of triaxial accelerometer measurement of gait ataxia is higher than that of the scale for the assessment and rating of ataxia in the early stages of spinocerebellar degeneration	Cerebellum	18(4)	721-730	2019
野村 太一, 大嶋 祐貴, 芳野 正修, 松島 理明, 矢部 一郎, 佐々木 秀直	高齢発症で家族歴の明らかではない遺伝性トランスサイレチン型アミロイドポリニューロパチーの2例	臨床神経	60(10)	688-692	2020
Yoshii K, Takahashi-Iwata I, Shirai S, Kobayashi S, Yabe I, Sasaki H.	A retrospective epidemiological study of tick-borne encephalitis virus in patients with neurological disorders in Hokkaido, Japan	Microorganisms	8(11)	1672	2020
Takahashi-Iwata I, Yabe I, Kudo A, Eguchi K, Wakita M, Shirai S, Matsushima M, Toyoshima T, Chiba S, Tanikawa S, Tanaka S, Satoh K, Kitamoto T, Sasaki H.	MM2 cortical form of sporadic Creutzfeldt-Jakob disease without progressive dementia and kinetic mutism: A case deviating from current diagnostic criteria	J Neurol Sci	412	116759	2020
佐藤智香, 加納崇裕, 矢部一郎, 佐々木秀直	免疫療法が奏効した小細胞肺癌合併抗CV2/CRMP5抗体陽性脊髄症の1例	臨床神経	60(8)	560-564	2020

Iwata Y, Kitajima S, Yamahana J, Shimomura S, Yoneda-Nakagawa S, Sakai N, Furuichi K, Ogura H, <u>Sato K</u> , Toyama T, Yamamura Y, Miyagawa T, <u>Hara A</u> , Shimizu M, Ohkawa R, Kurano M, Yatomi Y, Wada T.	Higher serum levels of autotaxin and phosphatidylserine-specific phospholipase A 1 in patients with lupus nephritis.	Int J Rheum Dis	24(2)	231-239	2020
Tran TTT, <u>Hara A</u> , Kitagawa K, Kitajima S, Toyama T, Iwata Y, Sakai N, Shimizu M, Kaneko S, Furuichi K, Wada T.	Relationship between autoantibodies to erythropoietin receptor and renal outcome in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis	Biomarkers	25(2)	194-200	2020
Nagasaka K, Harigai M, Hagino N, <u>Hara A</u> , Horita T, Hayashi T, Itabashi M, Ito S, Katsumata Y, Kawashima S, Naniwa T, Sada KE, Nango E, Nakayama T, Tsutsumino M, Yamagata K, Homma S, Arimura Y.	Systematic review and meta-analysis for 2017 clinical practice guidelines of the Japan research committee of the ministry of health, labour, and welfare for intractable vasculitis for the management of ANCA-associated vasculitis	Mod Rheumatol	29(1)	119-129	2019
<u>Hara A</u> , Wada T, Sada KE, Amano K, Doibashi H, Harigai M, Takasaki Y, Yamada H, Hasegawa H, Hayashi T, Fujimoto S, Muso E, Kawakami T, Homma S, Yoshida M, Hirahashi J, Ogawa N, Ito S, Makino H, Arimura Y; Research Committee on Intractable Vasculitides, and the Strategic Study Group to Establish the Evidence for Intractable Vasculitis Guideline.	Risk Factors for Relapse of Antineutrophil Cytoplasmic Antibody-associated Vasculitis in Japan: A Nationwide, Prospective Cohort Study	J Rheumatol	45(4)	521-528	2018